Skip to main content
. Author manuscript; available in PMC: 2016 Sep 1.
Published in final edited form as: Epidemiology. 2015 Sep;26(5):690–699. doi: 10.1097/EDE.0000000000000355

Figure 1.

Figure 1

Dissemination of Oxaliplatin: Receipt of Oxaliplatin vs. 5-fluorouracil for Stage III Colon Cancer By Month and Definition of Calendar Time Instrumental Variable (N=3660)

Points indicate the percentage of patients in each month receiving oxaliplatin or 5-FU. Grey shading indicates excluded patients due to interim period (October 2004-February 2005) and the truncation period of June 2007 and later. For illustrative purposes, diffusion patterns for each treatment are fitted with fourth-order polynomial trendline. The intersection point of lines is not statistically meaningful in terms of dissemination activity. Due to SEER-Medicare confidentiality requirements, treatment years 2003 and 2004 are combined.